BioAtla (NASDAQ:BCAB) Stock Price Down 1.3% – Time to Sell?

BioAtla, Inc. (NASDAQ:BCAB)’s stock price fell 1.3% during trading on Monday . The company traded as low as $1.31 and last traded at $1.48. Approximately 18,692 shares were traded during mid-day trading, a decline of 68% from the average daily volume of 57,597 shares. The stock had previously closed at $1.50.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioAtla in a research note on Monday, August 31st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, BioAtla currently has an average rating of “Hold” and a consensus target price of $200.00.

BioAtla Price Performance

The stock has a 50 day moving average price of $2.91 and a two-hundred day moving average price of $4.54. The company has a market capitalization of $2.83 million, a price-to-earnings ratio of -0.07 and a beta of 0.71.

BioAtla (NASDAQ:BCAB) last issued its quarterly earnings results on Thursday, August 13th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($8.50) by $8.64. The company had revenue of $6.50 million for the quarter, compared to analyst estimates of $6.50 million.

Institutional Trading of BioAtla

A hedge fund recently raised its position in BioAtla stock. ADAR1 Capital Management LLC increased its stake in BioAtla, Inc. (NASDAQ:BCAB) by 24.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 228,107 shares of the company’s stock after purchasing an additional 45,000 shares during the period. ADAR1 Capital Management LLC owned 13.74% of BioAtla worth $37,000 as of its most recent SEC filing. 77.23% of the stock is currently owned by institutional investors and hedge funds.

BioAtla Company Profile

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.